Clinical Trials Browser

Completed × INDUSTRY × ridaforolimus × Clear all

NCT00694083 2024-05-21

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Phase 1 Completed

Neoplasms

NCT00874731 2019-05-06

MK-8669-037

Phase 1 Completed

23 enrolled 14 charts

Neoplasm Metastasis

NCT01380184 2019-04-19

MK-8669-059

Phase 1 Completed

15 enrolled 15 charts

Neoplasms, Recurrence

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

NCT01431547 2016-06-17

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT00110188 2015-11-20

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Phase 2 Completed

Neoplasms, Prostatic Neoplasms

NCT00060632 2015-08-27

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00060645 2015-08-27

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00736970 2015-08-27

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Phase 2 Completed

Breast Neoplasms

NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Phase 1 Completed

BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT00086125 2015-08-19

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Phase 2 Completed

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Recurrence, Hematologic Neoplasms, Primary Myelofibrosis

NCT00087451 2015-08-19

Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)

Phase 1 Completed

Glioblastoma, Glioma, Gliosarcoma

NCT00777959 2015-08-19

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Phase 2 Completed

Prostatic Neoplasms

NCT00288431 2015-07-22

Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

Phase 1 Completed

Neoplasms, Sarcoma

NCT00739830 2015-07-01

Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

Phase 2 Completed

Endometrial Neoplasms

NCT01010672 2015-04-30

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Phase 2 Completed

Sarcoma

NCT01071304 2015-04-10

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Phase 1 Completed

Neoplasm Metastasis, Recurrence

NCT00122343 2015-02-19

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Phase 2 Completed

Neoplasms, Endometrial Neoplasms

NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Phase 2 Completed

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma

NCT00538239 2015-02-13

SUCCEED

Phase 3 Completed

Bone Neoplasms, Sarcoma

NCT00781846 2015-02-13

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT00112372 2015-02-12

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01220570 2015-01-21

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Phase 1 Completed

Breast Neoplasms